MedTrace Logo

Response of United Kingdom (UK) Infants to a Reduced Primary Schedule With Meningococcal C and Pneumococcal Conjugate Vaccines

NCT00197808 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 392

Last updated 2020-10-01

No results posted yet for this study

Summary

The purpose of the study is to evaluate the immune responses of UK infants after one or two doses of pneumococcal conjugate vaccine or one or two doses of three different types of meningococcal conjugate vaccine given at either two and three or two and four months of age.

Conditions

  • Pneumococcal Infections
  • Meningococcal Infections

Interventions

BIOLOGICAL

menjugate

men C conjugate vaccine

BIOLOGICAL

Men C conjugate vaccine

men C conjugate vaccine

BIOLOGICAL

Men C conjugate

men C conjugate vaccine

BIOLOGICAL

Men C Conjugate

men C conjugate vaccine

BIOLOGICAL

Men C conjugate

men C conjugate vaccine

BIOLOGICAL

Men C conjugate

men C conjugate vaccine

Sponsors & Collaborators

  • Public Health England

    lead OTHER_GOV

Principal Investigators

  • Elizabeth Coates, PhD · Public Health England

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
7 Weeks
Max Age
11 Weeks
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-04-30
Primary Completion
2010-01-31
Completion
2010-01-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00197808 on ClinicalTrials.gov